Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis
Retrospective analysis finds tenofovir alafenamide may provide similar virologic response with better renal safety in HBV-related decompensated cirrhosis patients.
Key Points
Tenofovir alafenamide demonstrated comparable virologic response to tenofovir disoproxil fumarate, achieving significant suppression of HBV DNA levels.
After 48 weeks, 13.1% of patients had detectable HBV DNA, a significant drop from 27.9%, with tenofovir alafenamide showing superior renal safety.
This retrospective study employed propensity score matching to enhance comparability between tenofovir alafenamide and tenofovir disoproxil fumarate cohorts.
Findings suggest tenofovir alafenamide should be considered in treatment protocols for managing HBV-related decompensated cirrhosis.